[Federal Register Volume 62, Number 30 (Thursday, February 13, 1997)]
[Notices]
[Pages 6802-6803]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-3659]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Manufacturer of Controlled Substances Application
Pursunat to Sec. 1301.43(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 11, 1996, Isotec,
Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application, which
was received for processing December 30, 1996, by renewal to the Drug
Enforcement Administration (DEA) for registration as a bulk
manufacturer of the basic classes of controlled substances listed
below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235).......................................... I
Methcathinone (1237)...................................... I
N-Ethylamphetamine (1475)................................. I
N,N-Dimethylamphetamine (1480)............................ I
Aminorex (1585)........................................... I
Methaqualone (2565)....................................... I
Lysergic acid diethylamide (7315)......................... I
Tetrahydrocannabinols (7370).............................. I
Mescaline (7381).......................................... I
2,5-Dimethoxyamphetamine (7396)........................... I
3,4-Methylenedioxyamphetamine (7400)...................... I
3,4-Methylenedioxy-N-ethylamphetamine (7404).............. I
3,4-Methylenedioxymethamphetamine (7405).................. I
4-Methoxyamphetamine (7411)............................... I
Psilocybin (7437)......................................... I
Psilocyn (7438)........................................... I
N-Ethyl-1-phenylcyclohexylamine (7455).................... I
Dihydromorphine (9145).................................... I
Normorphine (9313)........................................ I
Acetylmethadol (9601)..................................... I
Alphacetylmethadol Except Levo-Alphacetylmethadol (9603).. I
Normethadone (9635)....................................... I
3-Methylfentanyl (9813)................................... I
Amphetamine (1100)........................................ II
Methamphetamine (1105).................................... II
Methylphenidate (1724).................................... II
Amobarbital (2125)........................................ II
Pentobarbital (2270)...................................... II
Secobarbital (2315)....................................... II
1-Phenylcyclohexylamine (7460)............................ II
Phencyclidine (7471)...................................... II
Phenylacetone (8501)...................................... II
1-Piperidinocyclohexanecarbonitrile (8603)................ II
Codeine (9050)............................................ II
Dihydrocodeine (9120)..................................... II
Oxycodone (9143).......................................... II
Hydromorphone (9150)...................................... II
Benzoylecgoine (9180)..................................... II
Ethylmorphine (9190)...................................... II
Hydrocodone (9193)........................................ II
Isomethadone (9226)....................................... II
Meperidine (9230)......................................... II
Methadone (9250).......................................... II
Methadone intermediate (9254)............................. II
Dextropropoxyphene, bulk (non-dosage forms) (9273)........ II
Morphine (9300)........................................... II
Levo-Alphacetylmethadol (9648)............................ II
Oxymorphone (9652)........................................ II
Fentanyl (9801)........................................... II
------------------------------------------------------------------------
The firm plans to use small quantities of the listed controlled
substances to produce standards for analytical laboratories.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the above application.
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug
[[Page 6803]]
Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative
(CCR), and must be filed no later than April 14, 1997.
Dated: January 27, 1997.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 97-3659 Filed 2-12-97; 8:45 am]
BILLING CODE 4410-09-M
